Cancer Treatment with Radioactive Labeled Antibodies
The potential of radioimmunotherapy based upon monoclonal antibodies has elicited considerable excitement within the scientific community. This type of disease targeting has been a long-standing goal of medicine. Bale  explored the use of polyclonal antibodies produced against fibrin and labeled with I-131 to deliver radiation therapy to tumors more than 20 years ago. The potential usefulness of this approach has been demonstrated , but success was limited by inadequate specificity of these polyclonal antibodies. The superiority of monoclonal antibodies over conventional polyclonal antisera has been demonstrated . Monoclonal antibodies are uniquely attractive targeting molecules. Two other technological developments have occurred at precisely the same time as the hybridization technology for producing monoclonal antibody so that the simultaneous collision of these three technologies provides a unique opportunity for provision of radionuclide therapy based upon not only the specificity of monoclonal antibodies, but also treatment planning techniques of the type which have proved necessary in external beam and radionuclide sealed source radiation therapy. Contrary to common misconception, radionuclide therapy does not necessarily require more favorable target to nontarget relationships than radionuclide imaging. The critical element for radionuclide therapy is the nature of the nontarget or critical organ and its radiosensitivity.
KeywordsToxicity Lymphoma Attenuation Leukemia Boronated
Unable to display preview. Download preview PDF.
- 3.DeNardo GL, DeNardo SJ (1983) Perspectives on the future of radioimmunodiagnosis and radioimmunotherapy of cancer. In: Burchiel SW, Rhodes BA (eds) Radioimmunoimaging and radioimmunotherapy. Elsevier, New York, pp 41–60Google Scholar
- 4.Brady LW, Order SE, Leigel SA, Markoe AM (1984) Radionuclides for systemic on-cotherapy. Cancer Treat Symp 1:127–134Google Scholar
- 8.Order SE (1982) Monoclonal antibodies: potential role in radiation therapy and oncology. Int J Rad Oncol Biol Phys 8:1193–1201Google Scholar
- 12.DeNardo SJ, Jungerman JA, DeNardo GL, Lagunas-Solar MC, Cole WC, Meares CF (1984) The choice of radionuclides for radioimmunotherapy. In: The developing role of short-lived radionuclides in nuclear medicine practice. Oak Ridge, Tennessee, Department of Energy Technical Information Center, CONF-82-523, NTIS, pp 396–409Google Scholar
- 21.DeNardo SJ, Erickson KL, Benjamini E (1980) Use of I-131 antibodies for radiation therapy. Clin Nucl Med 5:9 SGoogle Scholar
- 22.DeNardo SJ, Erickson KL, Benjamini E, Hines H, Scibeinski R (1981) Radioimmunotherapy for melanoma. Clin Res 29Google Scholar
- 23.DeNardo SJ, Erickson K, Benjamini E, Hines H, Scibienski R, DeNardo G (1982) Monoclonal antibodies for radiation therapy of melanoma. In: Raynaud C (ed) Nuclear medicine and biology. Pergamon, Paris, pp 182–185Google Scholar
- 24.DeNardo SJ, Hines HH, Erickson KL, DeNardo GL (1983) Evaluation of radiolabeled monoclonal antibody parameters necessary for cancer immunotherapy. In: Chabner BA (ed) Rational basis for chemotherapy. Liss, New York, pp 379–387Google Scholar
- 26.Epstein AL, Zimmer AM, Spies SM, Mills SL, DeNardo GL, DeNardo SJ (1984) Radioimmunodetection of human B-cell lymphomas with a radiolabeled tumor-specific monoclonal antibody (Lym-1). Proceedings of the 2nd International conference on malignant lymphoma. Nijhoff, BostonGoogle Scholar
- 27.Cole W, DeNardo SJ, Meares C, DeNardo G, O’Brien H (1983) Development of copper- 67 chelate conjugated monoclonal antibodies for radioimmunotherapy. J Nucl Med 24(5):P30Google Scholar
- 32.Epenetos AA (1984) Antibody-guided irradiation of malignant lesions: three cases illustrating a method of treatment. Lancet: 1441–1443Google Scholar